Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
Regeneron posts phase 3 win, advancing push to muscle in on gMG
Regeneron plans to file for FDA approval of its siRNA candidate in the increasingly competitive generalized myasthenia gravis market.
Nick Paul Taylor
Aug 26, 2025 9:41am
RNA biotech emerges with $52M and clinical rare disease asset
Aug 25, 2025 10:13am
Federal mRNA vax grant cuts includes unrelated project
Aug 7, 2025 2:20pm
Biogen blueprints $1B CNS deal with RNAi biotech
May 27, 2025 10:55am
CRISPR Tx, Sirius pen collab with a focus on thrombotic disease
May 20, 2025 3:59am
AbbVie tosses ADARx $335M for siRNA options deal
May 14, 2025 9:00am
